GeneTherapy: 2nd generation therapies from AMT, INSERM and ArkTherapeutics

AMT, INSERM and Ark Therapeutics shared goal of achieving an approved gene therapy has led them all to explore what are becoming known as the 2nd generation therapies, and they will be discussing these ideas at the World Gene Therapy Congress in London later this year. Prof Alain Fischer from INSERM will be delivering his recent results in his work …

#GeneTherapy #Manufacturing at #ArkTherapeutics

Ark Therapeutics and PsiOxus Therapeutics Ltd have announced that their partnership has successfully achieved its first milestone, by the timely manufacture of PsiOxus’s ColoAd1 oncoloytic adenoviral product. The material was manufactured at Ark’s facility in Kuopio, Finland, using Ark’s proprietary suspension based single use process (“ATOSUS”), which was able to achieve the required product quality and demonstrate capability to exceed …